HCAT Stock Forecast & Price Target

Health Catalyst is supported by a favorable demand profile in a business undergoing transition, with FY26 gross bookings guidance of $22M-$26M and an implied level of roughly $25M viewed as healthy one quarter into the year. Management also cited strong Q1 Ignite-related bookings, including a large expansion, and existing-customer selling is more than 2x as effective, which supports efficient growth. While the end market and competition remain pressured, the company’s differentiated ability to layer analytics on top of a large data warehouse, plus optional upside from a potential acquisition at a substantive premium, strengthens the positive outlook.

Health Catalyst is facing a fundamentally weaker mix and visibility profile as the Vitalware divestiture removed a meaningful earnings contributor, with management disclosing about $37 million of Vitalware revenue in 2025 and $11.4 million of 1H'26 adj-EBITDA from the segment. FY'26 guidance was reset to $260 million-$265 million of revenue and $30 million-$33 million of adj-EBITDA, implying a sharp back-half step-down and reflecting churn, down-sell, and DOS-to-Ignite migration risk that persists through 2027. Despite a $82 million pro-forma cash balance and no debt, the go-forward business still needs proof it can reaccelerate revenue and convert cost actions into durable profitable growth, while professional services softness and a difficult hospital spending environment remain key headwinds.